Open AccessA novel synthetic compound shows antioxidant and anti- inflammatory activity and alleviates cognitive deficits in rats for the treatment of Alzheimer’s disease
Author(s) -
Jing Xie,
Rui Su,
Danna Wu,
Yeyu Qin,
Yun Xiong
Publication year - 2021
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 19
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm-21-1983
Subject(s) - resveratrol , neuroprotection , antioxidant , pharmacology , medicine , trolox , reactive oxygen species , endogeny , nitric oxide , dichlorofluorescein , microglia , amyloid beta , biochemistry , chemistry , immunology , inflammation , disease , dpph
Alzheimer's disease (AD) is a progressive dementia, and β-amyloid (Aβ) accumulation is widely regarded as the primary pathogenesis of AD. A new synthetic compound, 8-hydroxyquinoline-resveratrol derivative (E)-5-(4-hydroxystyryl)quinolin-8-ol (10c) was evaluated as a possible anti-AD agent.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom